Jean-François Lebeau et Andrée Tremblay v. Syngenta AG et als.

Reference :

750-06-000007-218

Complaint date :

No description

Status :

Provisional judgment

Place of jurisdiction :

Canada, Saint-Hyacinthe district (Province of Quebec)

Plaintiffs types :

Individuals

Plaintiffs names :

Jean-François Lebeau, Andrée Tremblay et al.

Defendants :

Syngenta

Lawyers for Health and Environmental Justice :

Caroline Perrault, Frédérique Langis, Daniel Bach (Siskinds, Desmeules, Avocats, s.e.n.c.r.l.)

Case nature :

Civil court

Specificities :

Class action

Type(s), Product(s), Active substance(s) :

Herbicide, Paraquat, Gramoxone

Requests :

Seeking financial compensation on behalf of all Canadians who have been diagnosed with Parkinson’s after using and/or being exposed to Gramoxone® and its active ingredient, paraquat, since its entry into the Canadian market (on or about July 1, 1963). 

Name of the Court :

Superior Court, Class Actions Division of Saint-Hyacinthe district (Province of Quebec), Canada

Jurisdiction level :

No description

Decision date :

July 27, 2022

Decision nature :

Positive

Decision content :

The Court finds that the plaintiffs satisfy the conditions required for the institution of a class action. It authorizes the institution of the class action in the form of a statement of claim for damages; and grants the plaintiffs, Jean-François Lebeau and Andrée Tremblay, the status of representative plaintiffs.

Legal basis :

Court Ruling :

Link to the ruling

Summary :

On July 27, 2022, the Superior Court of Quebec approved the class action for Canadians diagnosed with Parkinson's disease after having used and/or been exposed to Gramoxone since July 1, 1963, and their families. On October 24, 2022, class action lawyers filed a statement of claim with the Superior Court, in the district of Saint-Hyacinthe. Among other things, the Court will have to determine whether Gramaxone increases the risk of developing Parkinson's disease for people who have been repeatedly exposed to it, through inhalation, ingestion or skin contact. If the answer is yes, the Court will also have to establish whether the defendant Syngenta companies have failed in their duty to provide adequate, sufficient and timely information about this danger, namely the increased risk of developing Parkinson's disease, or about the means of avoiding it.

Two other class actions have been filed in Ontario (CV-21-00666775-00CP) and British Columbia (VLC-S-S-217598).

Scientific references :

No scientifice reference for this case.